At one level, the current petition clearly amounts to overkill. There’s no reason for all pandemic-related IPR to be suspended. Few developing countries will be interested, for example, in the vaccine produced by Moderna Inc., which requires the sort of super-cooled storage facilities they would struggle to build.
Most had already bet big on the vaccine from AstraZeneca
Plc and the University of Oxford, which the company has promised to sell at cost to many developing countries. With news
this weekend that the vaccine was, on average, 70% effective against preventing Covid-19, any argument that a wholesale suspension of property rights is needed to prevent poor-country taxes flowing into Big Pharma’s coffers begins to sound quite thin.
Yet the fact remains that if those capital flows are forced to materialize — if not for vaccines, then as royalties for therapeutic treatments or cutting-edge tests — then developing countries can and will revolt. We need to ensure poorer countries aren’t pushed to their limits if we want to avoid a breakdown in the global acknowledgement of IPR that would set back innovation worldwide.
This is the first test of importance that the global intellectual property system has faced — and it will not be the last. A future in which owners of algorithms, capital, data or platforms in the West exact unending rents from consumers and governments in poorer countries is far less likely than a wholesale repudiation of their right to do so by the rest of the world. An intellectual property regime that is not flexible enough to manage this crisis is one that will break under the weight of that techno-dystopia.
In other words, it is in everyone’s interest — including the residents of the world’s poorest countries, who depend upon innovation in the world’s richest nations to improve their lives — to head off this disgruntlement before it has a chance to gather political momentum. Some corporations recognize this. AstraZeneca, for example, has promised not to profit off the vaccine as long as Covid-19 is a pandemic (though how they will declare the pandemic is at an end remains mysterious).
Some rich-country leaders do as well. Boris Johnson hosted a global vaccine conference and the United Kingdom has so far committed $700 million to the shared vaccine fund, COVAX. French President Emmanuel Macron has helped set up the Access to Covid-19 Tools Accelerator, or ACT-A, which offers the best chance of distributing not just vaccines, but also diagnostic tests and therapeutic treatments.
Yet most rich-country governments have produced pandemic-response packages that are sharply nationalist and inward-looking in nature. ACT-A’s $38 billion budget is less than 1% of the amount that the Western world has committed to its lavish stimulus packages. And still Macron’s initiative is struggling for cash, having raised only $3 billion so far.
The biggest culprit has been the United States. Neither President Donald Trump nor Democrats in Congress have shown any interest in helping fund this effort, even though the country’s hopes for future prosperity depend on a functional global IPR system. If President-elect Joe Biden wants to demonstrate that the U.S. is once again a good-faith contributor to global efforts, he could start by promising that his administration will do what’s needed to ensure that ACT-A is fully funded. If the U.S. takes a back seat even under Biden, its hopes of recovering global respect and leadership will be truly finished.
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.